

FORM 7
MONTHLY PROGRESS REPORT

April 2017

Name of CSE Issuer: **True Leaf Medicine International Ltd. (the “Issuer”)**

Trading Symbol: **MJ**

Number of Outstanding Listed Securities: **61,413,093 common shares (plus 4,311,251 common shares reserved for issuance in the form of 1,818,396 warrants and 2,164,285 options)**

Date: **May 4, 2017**

Report on Business

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

During the past month, the Issuer generally continued to market its pet products and to develop its pet product line.

Specifically, on April 20, 2017, the Issuer announced that it had reached stage five of the process to acquire a license to produce and grow marijuana in Canada, thereby becoming one of over 100 companies with applications in the “Review” stage out of a total of 1,630 applicants under the MMPR/ACMPR.

In addition, on April 24, 2017, the Issuer announced that it had engaged a number of cannabis experts to guide it through the final stage in Health Canada’s review of the Issuer’s application, including persons or teams associated with Pipe Dreemz Inc., Protect-IP Global Solutions Inc., Eurofins Scientific, and Ample Organics.

2. Provide a general overview and discussion of the activities of management.

Please see item 1.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None, except in the ordinary course of business.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None.

8. Describe the acquisition of new customers or loss of customers.

None, except in the ordinary course of business.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
Common shares	657,140	These shares were issued on April 27, 2017 upon the exercise of outstanding stock options at a price of \$0.185 per share	\$121,570.90 for general corporate purposes

⁽¹⁾ State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers or committee members.

None.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

None.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: May 4, 2017

Darcy Bomford
Name of Director or Senior
Officer

"Darcy Bomford"
Signature

Chief Executive Officer
Official Capacity

Issuer Details		
Name of Issuer: True Leaf Medicine International Ltd.	For Month End April 2017	Date of Report: YYYY/MM/DD 2017/05/04
Issuer Address: 100 Kalamalka Lake Road, Unit 32		
City/Province/Postal Code: Vernon, BC V1T 9G1	Issuer Fax No.: N/A	Issuer Telephone No. 778.475.5323
Contact Name: Darcy Bomford	Contact Position: President, CEO, Director	Contact Telephone No. 778.475.5323
Contact Email Address: darcy@trueleaf.com	Web Site Address: www.trueleaf.com	